Global Orphan Indication Drugs Market Research Report 2024(Status and Outlook)

Global Orphan Indication Drugs Market Research Report 2024(Status and Outlook)



Report Overview: An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as "orphan" is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research. The Global Orphan Indication Drugs Market Size was estimated at USD 642.34 million in 2023 and is projected to reach USD 736.24 million by 2029, exhibiting a CAGR of 2.30% during the forecast period. This report provides a deep insight into the global Orphan Indication Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Orphan Indication Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market. In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Orphan Indication Drugs market in any manner. Global Orphan Indication Drugs Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Key Company Bristol-Myers Squibb Roche Novartis Johnson & Johnson Pfizer Amgen Sanofi AstraZeneca Takeda Vertex Pharmaceuticals AbbVie Biogen Eli Lilly Market Segmentation (by Type) Biologics Non-Biologics Market Segmentation (by Application) Hospital Pharmacy Retail Pharmacy Online Sales Geographic Segmentation • North America (USA, Canada, Mexico) • Europe (Germany, UK, France, Russia, Italy, Rest of Europe) • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) • South America (Brazil, Argentina, Columbia, Rest of South America) • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA) Key Benefits of This Market Research: • Industry drivers, restraints, and opportunities covered in the study • Neutral perspective on the market performance • Recent industry trends and developments • Competitive landscape & strategies of key players • Potential & niche segments and regions exhibiting promising growth covered • Historical, current, and projected market size, in terms of value • In-depth analysis of the Orphan Indication Drugs Market • Overview of the regional outlook of the Orphan Indication Drugs Market: Key Reasons to Buy this Report: • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change • This enables you to anticipate market changes to remain ahead of your competitors • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly • Provision of market value (USD Billion) data for each segment and sub-segment • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis • Provides insight into the market through Value Chain • Market dynamics scenario, along with growth opportunities of the market in the years to come • 6-month post-sales analyst support Customization of the Report In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met. Note: this report may need to undergo a final check or review and this could take about 48 hours. Chapter Outline Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods. Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Orphan Indication Drugs Market and its likely evolution in the short to mid-term, and long term. Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market. Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis. Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc. Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years. Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years. Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Orphan Indication Drugs
1.2 Key Market Segments
1.2.1 Orphan Indication Drugs Segment by Type
1.2.2 Orphan Indication Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Orphan Indication Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Orphan Indication Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Orphan Indication Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Orphan Indication Drugs Market Competitive Landscape
3.1 Global Orphan Indication Drugs Sales by Manufacturers (2019-2024)
3.2 Global Orphan Indication Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Orphan Indication Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Orphan Indication Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Orphan Indication Drugs Sales Sites, Area Served, Product Type
3.6 Orphan Indication Drugs Market Competitive Situation and Trends
3.6.1 Orphan Indication Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Orphan Indication Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Orphan Indication Drugs Industry Chain Analysis
4.1 Orphan Indication Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Orphan Indication Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Orphan Indication Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Orphan Indication Drugs Sales Market Share by Type (2019-2024)
6.3 Global Orphan Indication Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Orphan Indication Drugs Price by Type (2019-2024)
7 Orphan Indication Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Orphan Indication Drugs Market Sales by Application (2019-2024)
7.3 Global Orphan Indication Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Orphan Indication Drugs Sales Growth Rate by Application (2019-2024)
8 Orphan Indication Drugs Market Segmentation by Region
8.1 Global Orphan Indication Drugs Sales by Region
8.1.1 Global Orphan Indication Drugs Sales by Region
8.1.2 Global Orphan Indication Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Orphan Indication Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Orphan Indication Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Orphan Indication Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Orphan Indication Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Orphan Indication Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Orphan Indication Drugs Basic Information
9.1.2 Bristol-Myers Squibb Orphan Indication Drugs Product Overview
9.1.3 Bristol-Myers Squibb Orphan Indication Drugs Product Market Performance
9.1.4 Bristol-Myers Squibb Business Overview
9.1.5 Bristol-Myers Squibb Orphan Indication Drugs SWOT Analysis
9.1.6 Bristol-Myers Squibb Recent Developments
9.2 Roche
9.2.1 Roche Orphan Indication Drugs Basic Information
9.2.2 Roche Orphan Indication Drugs Product Overview
9.2.3 Roche Orphan Indication Drugs Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Orphan Indication Drugs SWOT Analysis
9.2.6 Roche Recent Developments
9.3 Novartis
9.3.1 Novartis Orphan Indication Drugs Basic Information
9.3.2 Novartis Orphan Indication Drugs Product Overview
9.3.3 Novartis Orphan Indication Drugs Product Market Performance
9.3.4 Novartis Orphan Indication Drugs SWOT Analysis
9.3.5 Novartis Business Overview
9.3.6 Novartis Recent Developments
9.4 Johnson and Johnson
9.4.1 Johnson and Johnson Orphan Indication Drugs Basic Information
9.4.2 Johnson and Johnson Orphan Indication Drugs Product Overview
9.4.3 Johnson and Johnson Orphan Indication Drugs Product Market Performance
9.4.4 Johnson and Johnson Business Overview
9.4.5 Johnson and Johnson Recent Developments
9.5 Pfizer
9.5.1 Pfizer Orphan Indication Drugs Basic Information
9.5.2 Pfizer Orphan Indication Drugs Product Overview
9.5.3 Pfizer Orphan Indication Drugs Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 Amgen
9.6.1 Amgen Orphan Indication Drugs Basic Information
9.6.2 Amgen Orphan Indication Drugs Product Overview
9.6.3 Amgen Orphan Indication Drugs Product Market Performance
9.6.4 Amgen Business Overview
9.6.5 Amgen Recent Developments
9.7 Sanofi
9.7.1 Sanofi Orphan Indication Drugs Basic Information
9.7.2 Sanofi Orphan Indication Drugs Product Overview
9.7.3 Sanofi Orphan Indication Drugs Product Market Performance
9.7.4 Sanofi Business Overview
9.7.5 Sanofi Recent Developments
9.8 AstraZeneca
9.8.1 AstraZeneca Orphan Indication Drugs Basic Information
9.8.2 AstraZeneca Orphan Indication Drugs Product Overview
9.8.3 AstraZeneca Orphan Indication Drugs Product Market Performance
9.8.4 AstraZeneca Business Overview
9.8.5 AstraZeneca Recent Developments
9.9 Takeda
9.9.1 Takeda Orphan Indication Drugs Basic Information
9.9.2 Takeda Orphan Indication Drugs Product Overview
9.9.3 Takeda Orphan Indication Drugs Product Market Performance
9.9.4 Takeda Business Overview
9.9.5 Takeda Recent Developments
9.10 Vertex Pharmaceuticals
9.10.1 Vertex Pharmaceuticals Orphan Indication Drugs Basic Information
9.10.2 Vertex Pharmaceuticals Orphan Indication Drugs Product Overview
9.10.3 Vertex Pharmaceuticals Orphan Indication Drugs Product Market Performance
9.10.4 Vertex Pharmaceuticals Business Overview
9.10.5 Vertex Pharmaceuticals Recent Developments
9.11 AbbVie
9.11.1 AbbVie Orphan Indication Drugs Basic Information
9.11.2 AbbVie Orphan Indication Drugs Product Overview
9.11.3 AbbVie Orphan Indication Drugs Product Market Performance
9.11.4 AbbVie Business Overview
9.11.5 AbbVie Recent Developments
9.12 Biogen
9.12.1 Biogen Orphan Indication Drugs Basic Information
9.12.2 Biogen Orphan Indication Drugs Product Overview
9.12.3 Biogen Orphan Indication Drugs Product Market Performance
9.12.4 Biogen Business Overview
9.12.5 Biogen Recent Developments
9.13 Eli Lilly
9.13.1 Eli Lilly Orphan Indication Drugs Basic Information
9.13.2 Eli Lilly Orphan Indication Drugs Product Overview
9.13.3 Eli Lilly Orphan Indication Drugs Product Market Performance
9.13.4 Eli Lilly Business Overview
9.13.5 Eli Lilly Recent Developments
10 Orphan Indication Drugs Market Forecast by Region
10.1 Global Orphan Indication Drugs Market Size Forecast
10.2 Global Orphan Indication Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Orphan Indication Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Orphan Indication Drugs Market Size Forecast by Region
10.2.4 South America Orphan Indication Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Orphan Indication Drugs by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Orphan Indication Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Orphan Indication Drugs by Type (2025-2030)
11.1.2 Global Orphan Indication Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Orphan Indication Drugs by Type (2025-2030)
11.2 Global Orphan Indication Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Orphan Indication Drugs Sales (Kilotons) Forecast by Application
11.2.2 Global Orphan Indication Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings